Allergy and Clinical Immunology

Episodes 1-13 of 13

• 

  RestartResume

  An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC

  RestartResume

  An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC

  Project Oncology®

  An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC

• 

  RestartResume

  Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist

  RestartResume

  Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist

  Project Oncology®

  Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist

• 

  RestartResume

  Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial

  RestartResume

  Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial

  Project Oncology®

  Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial

• 

  RestartResume

  A Unique Look at the Current and Future Directions of Cancer Vaccines

  RestartResume

  A Unique Look at the Current and Future Directions of Cancer Vaccines

  Project Oncology®

  A Unique Look at the Current and Future Directions of Cancer Vaccines

  • 

    

    Lillian Siu, MD, FRCPC

• 

  RestartResume

  A Look at the Horizon of Cancer Vaccines

  RestartResume

  A Look at the Horizon of Cancer Vaccines

  Project Oncology®

  A Look at the Horizon of Cancer Vaccines

  • 

    

    Lillian Siu, MD, FRCPC

• 

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  MinuteCE®

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  MinuteCE®

  WHIM Syndrome (A Chronic Neutropenic Disorder): Uncouple the Complex for HCPs and Patients

  1.00 credit 7 episodes

  • 

    

    Jolan Walter, MD, PHD

  • 

    

    Teresa K. Tarrant, MD

  • 

    

    Peter E. Newburger, MD

  • 

    

    Jacob R. Bledsoe, MD

  1.00 credit 7 episodes

• 

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  RestartResume

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  MinuteCE®

  WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans

  1.00 program credit

  • 

    

    Jacob R. Bledsoe, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  MinuteCE®

  WHIM Syndrome Treatment: We Can Do Better!

  1.00 program credit

  • 

    

    Jolan Walter, MD, PHD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  MinuteCE®

  WHIM Syndrome: A Misguided Immune System!

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  MinuteCE®

  WHIM Syndrome: A Chronic Neutropenic Disorder

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  MinuteCE®

  WHIM Syndrome Management: The First FDA Approval for Patients

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit

• 

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  MinuteCE®

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit